Switch to:
More From Other Websites
Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority of Kyprolis® (carfilzomib) Over... Mar 01 2015
Amgen Announces the European Medicines Agency Acceptance of Kyprolis® (carfilzomib) Marketing... Feb 26 2015
Amgen Announces New Data from Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study in Patients... Dec 07 2014
Amgen and Onyx Announce Detailed Results from Phase 3 ASPIRE Study of Kyprolis® (carfilzomib) in... Dec 06 2014
Amgen Highlights New Data in The Treatment of Blood Cancers at ASH 2014 Nov 06 2014
Bayer and Onyx Report Phase 3 Study Results of NEXAVAR® (sorafenib) as Adjuvant Treatment for... Mar 11 2014
AstraZeneca buys US cancer drugs firm Aug 27 2013
US biotech giant Amgen to buy rival Onyx for $10.4 bln Aug 25 2013


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK